SQZ Biotechnologies Company – NYSE:SQZ

Add to watchlist

$0.543

+0.49

+968.27%

Market closed

Open in 2 days

-38.99%

month

-91.12%

quarter

-98.30%

year

Market Cap	12.82M
Enterprise value	N/A

P/E	-0.22
EV/Sales	-0.71
EV/EBITDA	0.18
Price/Sales	0.60
Price/Book	0.28
PEG ratio	N/A
EPS	N/A

Revenue	N/A
EBITDA	-59.64M
Income	N/A
Revenue Q/Q	-100%
Revenue Y/Y	-42.89%

Profit margin	-158.19%
Oper. margin	-454.18%
Gross margin	11%
EBIT margin	-454.18%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

SQZ Biotechnologies Company (NYSE:SQZ): Profit margin
Dec 2022	12.01M	30.49M	253.72%
Mar 2023	0	-17.11M
Jun 2023	178K	-16.77M	-9421.35%
Sep 2023	0	0

SQZ Biotechnologies Company (NYSE:SQZ): Earnings per share (EPS)
2023-08-03	0.6	-0.78

SQZ Biotechnologies Company (NYSE:SQZ): Debt to assets
Dec 2022	99900000	42.75M	42.79%
Mar 2023	73157000	33.00M	45.11%
Jun 2023	54148000	29.61M	54.69%
Sep 2023	29788000	27.90M	93.69%

SQZ Biotechnologies Company (NYSE:SQZ): Cash Flow
Dec 2022	-20.76M	-101K	331K
Mar 2023	-23.77M	-65K	0
Jun 2023	-15.27M	108K	0
Sep 2023	3.88M	0	0

SQZ Biotechnologies Company alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

SQZ Biotechnologies Company
Employees

SQZ Biotechnologies Company (NYSE:SQZ): Employee count
Aug 2023	53
Sep 2023	53
Oct 2023	53
Nov 2023	53
Dec 2023	53
Jan 2024	53
Feb 2024	53
Mar 2024	53
Apr 2024	53
May 2024	53
Jun 2024	53
Jul 2024	53

SQZ Biotechnologies Company
Hedge Funds Holdings Q1 2023

28.17% -15.04%

of SQZ is owned by hedge funds

19 -16

hedge funds hold SQZ stock

8.11M -4.53M

shares is hold by hedge funds

SQZ hedge funds holdings changes

SQZ Biotechnologies Company
Insider Trading

SQZ Biotechnologies Company (NYSE:SQZ): Insider trades (number of shares)
Period	Buy	Sel
Dec 2021	1850	0
May 2022	14326	0
Aug 2022	0	1183

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	15 Aug 2022	CAPASSO RICHARD officer: Officer Title - Principal Account.. officer: Officer Title - Princi..	Common Stock	1,183	$3.33	$3,935
Purchase	25 May 2022	JENSEN KLAVS F. director director	Common Stock	14,326	$3.52	$50,428
Option	12 Jan 2022	SHAREI ARMON director, officer..	Stock Option	13,000	$1.81	$23,530
Option	12 Jan 2022	SHAREI ARMON director, officer..	Common Stock	13,000	$1.81	$23,530
Option	22 Dec 2021	SCHULMAN AMY W director, 10 percent owner director, 10 percent owner	Stock Option	6,581	$4.59	$30,207
Option	22 Dec 2021	SCHULMAN AMY W director, 10 percent owner director, 10 percent owner	Stock Option	7,458	$4.59	$34,232
Option	22 Dec 2021	SCHULMAN AMY W director, 10 percent owner director, 10 percent owner	Stock Option	10,091	$2.02	$20,384
Option	22 Dec 2021	SCHULMAN AMY W director, 10 percent owner director, 10 percent owner	Common Stock	6,581	$4.59	$30,207
Option	22 Dec 2021	SCHULMAN AMY W director, 10 percent owner director, 10 percent owner	Common Stock	7,458	$4.59	$34,232
Option	22 Dec 2021	SCHULMAN AMY W director, 10 percent owner director, 10 percent owner	Common Stock	10,091	$2.02	$20,384

SQZ insider trading transactions

SQZ Biotechnologies Company
Patents

Status	Patent	Filling date	Issue date
Application	Application FORMULATIONS OF PBMCS Filling date: 28 Dec 2021 Issue date: 4 Aug 2022	28 Dec 2021	4 Aug 2022
Application	Application METHODS FOR TREATING CANCERS WITH MODIFIED PBMCS Filling date: 28 Dec 2021 Issue date: 28 Jul 2022	28 Dec 2021	28 Jul 2022
Application	Application FORMULATIONS OF ACTIVATING ANTIGEN CARRIERS Filling date: 28 Dec 2021 Issue date: 28 Jul 2022	28 Dec 2021	28 Jul 2022
Application	Application HIGH-THROUGHPUT MICROFLUIDIC CHIP HAVING PARALLELIZED CONSTRICTIONS FOR PERTURBING CELL MEMBRANES Filling date: 27 Dec 2021 Issue date: 30 Jun 2022	27 Dec 2021	30 Jun 2022
Application	Application MICROFLUIDIC CHIP HAVING INCREASED THROUGHPUT FOR USE IN A SYSTEM FOR DELIVERY OF A PAYLOAD INTO A CELL Filling date: 27 Dec 2021 Issue date: 30 Jun 2022	27 Dec 2021	30 Jun 2022
Application	Application ANUCLEATE CELL-DERIVED VACCINES Filling date: 24 Jan 2020 Issue date: 7 Apr 2022	24 Jan 2020	7 Apr 2022
Application	Application INTRACELLULAR DELIVERY OF BIOMOLECULES TO ENHANCE ANTIGEN PRESENTING CELL FUNCTION Filling date: 3 Oct 2019 Issue date: 16 Dec 2021	3 Oct 2019	16 Dec 2021
Application	Application POINT OF CARE SYSTEM FOR AUTOMATICALLY PROCESSING CELLS Filling date: 21 May 2021 Issue date: 25 Nov 2021	21 May 2021	25 Nov 2021
Application	Application INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODULATE ANTIBODY PRODUCTION Filling date: 4 Dec 2018 Issue date: 14 Oct 2021	4 Dec 2018	14 Oct 2021
Application	Application INTRACELLULAR DELIVERY OF BIOMOLECULES TO INDUCE TOLERANCE Filling date: 3 May 2017 Issue date: 13 May 2021	3 May 2017	13 May 2021

SQZ patents

SQZ Biotechnologies Company
Executives

Insider	Age	Compensation
Dr. Armon R. Sharei Ph.D. (1987) Co-Founder, Pres, Chief Executive Officer, Interim Principal Financial Officer & Director	38	$692,570
Ms. Teri Loxam (1972) Acting Chief Financial Officer	53	$633,030
Mr. Lawrence J. Knopf (1962) Gen. Counsel & Sec.	63	$474,450
Mr. Micah Zajic (1981) Chief Bus. Officer	44	$288,650

SQZ Biotechnologies Company
Latest News

Tuesday, 29 October 2024
04:27	Serica Energy reports temporary production halt at Triton	proactiveinvestors.co.uk
Wednesday, 2 October 2024
03:34	Serica Energy reveals bumper volumes from Bittern well	proactiveinvestors.co.uk
Tuesday, 10 September 2024
03:49	Serica Energy calls UK oil and gas tax regime “unjustifiably punitive”	proactiveinvestors.co.uk
Monday, 3 July 2023
13:30	NYSE to Commence Delisting Proceedings Against SQZ Biotechnologies Company (SQZ)	businesswire.com
Wednesday, 10 May 2023
20:31	SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates	Zacks Investment Research
Wednesday, 7 September 2022
16:30	SQZ Biotechnologies to Present at Upcoming Investor Conferences	Business Wire
Wednesday, 8 June 2022
14:30	Biopharmaceutical Stocks: The Bottoming Process Is Playing Out	Seeking Alpha
Wednesday, 1 June 2022
16:45	SQZ Biotechnologies to Present at Jefferies Healthcare Conference	Business Wire
Wednesday, 6 April 2022
16:45	SQZ Biotechnologies to Present at Upcoming Investor Conferences	Business Wire
Tuesday, 8 March 2022
16:45	SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting	Business Wire
Thursday, 2 December 2021
13:31	SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors	Benzinga
Monday, 29 November 2021
16:45	SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference	Business Wire
Monday, 15 November 2021
16:45	SQZ Biotechnologies to Present at the Stifel 2021 Virtual Healthcare Conference	Business Wire
Monday, 4 October 2021
06:45	SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting	Business Wire
Thursday, 30 September 2021
16:45	SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference	Business Wire
Monday, 27 September 2021
16:45	SQZ Biotechnologies to Present at Cantor Global Healthcare Conference	Business Wire
Monday, 13 September 2021
06:45	SQZ Biotechnologies Announces First Autoimmune Disease Indication for Tolerizing Antigen Carrier (TAC) Platform	Business Wire
Thursday, 9 September 2021
06:45	SQZ Biotechnologies to Present at Upcoming Health Care Conferences	Business Wire

Ideas & Opinions

Seeking Alpha 13 Aug 2022

Biopharmaceutical Stocks Continue To Perform Well, With Many Attractive Values Remaining
Seeking Alpha 8 Jun 2022

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Seeking Alpha 7 Feb 2022

AlloVir: A Comparative Study Of Its Manufacturing Process
Seeking Alpha 6 Sep 2021

MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile
Seeking Alpha 2 Jun 2021

ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas

Frequently Asked Questions (FAQ)

What's the price of SQZ Biotechnologies Company stock today?

One share of SQZ Biotechnologies Company stock can currently be purchased for approximately $0.54.
When is SQZ Biotechnologies Company's next earnings date?

Unfortunately, SQZ Biotechnologies Company's (SQZ) next earnings date is currently unknown.
Does SQZ Biotechnologies Company pay dividends?

No, SQZ Biotechnologies Company does not pay dividends.
How much money does SQZ Biotechnologies Company make?

SQZ Biotechnologies Company has a market capitalization of 12.82M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 22.4% to 21.03M US dollars. SQZ Biotechnologies Company made a loss 78.24M US dollars in net income (profit) last year or -$0.78 on an earnings per share basis.
What is SQZ Biotechnologies Company's stock symbol?

SQZ Biotechnologies Company is traded on the NYSE under the ticker symbol "SQZ".
What is SQZ Biotechnologies Company's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of SQZ Biotechnologies Company?

Shares of SQZ Biotechnologies Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are SQZ Biotechnologies Company's key executives?
SQZ Biotechnologies Company's management team includes the following people:
- Dr. Armon R. Sharei Ph.D. Co-Founder, Pres, Chief Executive Officer, Interim Principal Financial Officer & Director(age: 38, pay: $692,570)
- Ms. Teri Loxam Acting Chief Financial Officer(age: 53, pay: $633,030)
- Mr. Lawrence J. Knopf Gen. Counsel & Sec.(age: 63, pay: $474,450)
- Mr. Micah Zajic Chief Bus. Officer(age: 44, pay: $288,650)
Is SQZ Biotechnologies Company founder-led company?

Yes, SQZ Biotechnologies Company is a company led by its founder Dr. Armon R. Sharei Ph.D..
How many employees does SQZ Biotechnologies Company have?

As Jul 2024, SQZ Biotechnologies Company employs 53 workers.
When SQZ Biotechnologies Company went public?

SQZ Biotechnologies Company is publicly traded company for more then 4 years since IPO on 30 Oct 2020.
What is SQZ Biotechnologies Company's official website?

The official website for SQZ Biotechnologies Company is sqzbiotech.com.
Where are SQZ Biotechnologies Company's headquarters?

SQZ Biotechnologies Company is headquartered at 200 Arsenal Yards Boulevard, Watertown, MA.
How can i contact SQZ Biotechnologies Company?

SQZ Biotechnologies Company's mailing address is 200 Arsenal Yards Boulevard, Watertown, MA and company can be reached via phone at +61 77588672.

SQZ Biotechnologies Company

sqzbiotech.com

Exchange:

NYSE

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

+61 77588672

200 Arsenal Yards Boulevard
Watertown, MA 02472

CIK: 0001604477
ISIN: US78472W1045
CUSIP: 78472W104